New proteomic clock predicts biological age and major health risks across diverse populations

Study developed a proteomic age clock using plasma proteins to accurately predict biological age and associated health risks, offering a robust tool for forecasting age-related diseases and mortality.

J&J drops Addex’s epilepsy treatment after flunking in Phase II

J&J and Addex’s ADX71149 is a positive allosteric modulator (PAM) of metabotropic glutamate receptor-2 (mGlu2 receptor). Image Credit: eamesBot / Shutterstock. Johnson and Johnson (J&J)

July 23, 2024

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against

July 9, 2024

Orthofix hires new CEO, 2 months after former leaders ousted

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Massimo Calafiore, new Orthofix CEO Courtesy of

November 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.